Recapture of treatment response before or after switching to OL IXE through 104 weeks among patients randomised to placebo (IXE withdrawal) who experienced a flare and were retreated
| Total patients who flared and were switched to OL IXE retreatment | Placebo (IXE withdrawal) (N=28) | |
| ASDAS disease activity status | LDA | ID |
| Recaptured response before OL IXE retreatment, n | 4 | 1 |
| Recaptured response with OL IXE retreatment (≤16 weeks), n | 23 | 14 |
| Recaptured response with OL IXE retreatment (>16 weeks), n | 0 | 5 |
| Total patients who recaptured response by week 104, n (%) | 27/28 (96) | 20/28 (71) |
In each column, the denominator is 28. A total of 4 patients met the criteria for flare and were not retreated. 20 patients had achieved ASDAS ID, while 8 patients achieved ASDAS LDA before flare and OL IXE retreatment.
ASDAS, Ankylosing Spondylitis Disease Activity Score; ID, inactive disease; IXE, ixekizumab; LDA, low disease activity including ID; N, number of patients in the analysis population; OL, open-label.